Poster
179
(#179) Real-World Characteristics of Prescribers and Adult Patients Initiating Zuranolone or Antidepressants for the Treatment of Postpartum Depression
Psych Congress 2025
Abstract: Zuranolone (ZRN), a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors, was approved in the US (2023) as an oral, once-daily, 14-day treatment for adults with postpartum depression (PPD). This interim report describes real-world characteristics of adults with PPD initiating ZRN or antidepressants (ADTs) and prescribers of PPD treatment in 2023-2024 using retrospective claims data.
This study included females aged ≥18 years with ≥1 pregnancy claim and ≥1 PPD diagnostic claim (defined in this post-hoc analysis as the first PPD or major depressive disorder ICD-10-coded claim during or within 12 months after pregnancy) prior to initiating ZRN first-line (ZRN-1L), ZRN after first-line ADTs (ADT-ZRN), or first-line ADTs only (ADT-1L). Linked third-party ZRN claims were from a national specialty pharmacy; ADT claims were from a third-party database.
Patient baseline demographics, socioeconomic factors, and clinical characteristics were similar across ZRN-1L (n=691), ADT-ZRN (n=171), and ADT-1L (n=34,978) groups. OB/GYNs were the primary prescribers of both ZRN (73.6% of ZRN-1L patients; 48.6% of ADT-ZRN patients when prescribed ZRN) and ADTs (59.4% of ADT-ZRN patients when prescribed first-line ADTs; 35.2% of ADT-1L patients). PPD was most often diagnosed within 3 months postpartum (42.4% of ZRN-1L, 56.6% of ADT-ZRN, and 37.2% of ADT-1L patients). Most patients were prescribed first-line treatments within 30 days post-PPD diagnosis (ZRN-1L, 65.8%; ADT-1L, 58.1%); 44.2% of patients in the ADT-ZRN group were prescribed ZRN 1-3 months post-PPD diagnosis.
Patient demographics and clinical characteristics were similar across treatment groups. OB/GYNs were the primary prescribers of PPD treatments.
Short Description: Zuranolone is the only FDA-approved (2023) oral medication for adults diagnosed with postpartum depression (PPD). This study reports real-world characteristics of prescribers and patients initiating zuranolone first-line, zuranolone after first-line antidepressants, or first-line antidepressants. Patient demographics and clinical characteristics were similar across groups. OB/GYNs were the primary prescribers of treatment for PPD, with most treatments prescribed within 30 days of PPD diagnosis.
Name of Sponsoring Organization(s): Sage Therapeutics, Inc. and Biogen Inc.
This study included females aged ≥18 years with ≥1 pregnancy claim and ≥1 PPD diagnostic claim (defined in this post-hoc analysis as the first PPD or major depressive disorder ICD-10-coded claim during or within 12 months after pregnancy) prior to initiating ZRN first-line (ZRN-1L), ZRN after first-line ADTs (ADT-ZRN), or first-line ADTs only (ADT-1L). Linked third-party ZRN claims were from a national specialty pharmacy; ADT claims were from a third-party database.
Patient baseline demographics, socioeconomic factors, and clinical characteristics were similar across ZRN-1L (n=691), ADT-ZRN (n=171), and ADT-1L (n=34,978) groups. OB/GYNs were the primary prescribers of both ZRN (73.6% of ZRN-1L patients; 48.6% of ADT-ZRN patients when prescribed ZRN) and ADTs (59.4% of ADT-ZRN patients when prescribed first-line ADTs; 35.2% of ADT-1L patients). PPD was most often diagnosed within 3 months postpartum (42.4% of ZRN-1L, 56.6% of ADT-ZRN, and 37.2% of ADT-1L patients). Most patients were prescribed first-line treatments within 30 days post-PPD diagnosis (ZRN-1L, 65.8%; ADT-1L, 58.1%); 44.2% of patients in the ADT-ZRN group were prescribed ZRN 1-3 months post-PPD diagnosis.
Patient demographics and clinical characteristics were similar across treatment groups. OB/GYNs were the primary prescribers of PPD treatments.
Short Description: Zuranolone is the only FDA-approved (2023) oral medication for adults diagnosed with postpartum depression (PPD). This study reports real-world characteristics of prescribers and patients initiating zuranolone first-line, zuranolone after first-line antidepressants, or first-line antidepressants. Patient demographics and clinical characteristics were similar across groups. OB/GYNs were the primary prescribers of treatment for PPD, with most treatments prescribed within 30 days of PPD diagnosis.
Name of Sponsoring Organization(s): Sage Therapeutics, Inc. and Biogen Inc.
